LetsMD tops up Pre Series A round with an additional USD 1Mn investment

Gunjan Chauhan
Gunjan Chauhan
· 2 min read

Delhi-NCR based healthcare fintech start-up, LetsMD, has topped up its Pre Series A round with an additional investment of INR 4 crores from Orios Venture Partners. “The investment is a combination of a primary and a secondary transaction”, announced Nivesh   Khandelwal, founder and CEO, LetsMD.

Existing investors SRI Capital and Waterbridge ventures also participated in the secondary transaction. The overall size of the Pre Series A round was INR 13 crores.

In April 2018, the company had raised $1 million in Pre Series A round of funding led by SRI Capital and Thinkuvate with participation from existing investor Waterbridge Ventures.

Speaking on the funding, Khandelwal, said, “There will be a demand-supply gap in healthcare financing due to rising out-of-the-pocket expenses and healthcare inflation in the next five to 10 years. The focus has to be on ensuring the last mile availability of financing at tertiary care facilities. LetsMD aspires to create a viable option for financing the healthcare needs for people of all strata.”

Further Khandelwal said, “We are growing at 30% month on month and have expanded our offering to Mumbai and Kolkata as well. We plan to launch in Pune and Bengaluru by the end of this year. The majority of our individual angel investors have exited as we prepare the company for larger institutional rounds of financing, going forward.”

Founded in 2015 by Khandelwal, LetsMD allows users pay their medical bills in low interest EMIs at more than 300 hospitals across Delhi NCR, Mumbai and Kolkata.

Read Next

Granules India posts Rs 13,879 million revenue from operations at Q3FY26
Finance
January 28, 2026

Granules India posts Rs 13,879 million revenue from operations at Q3FY26

Net debt stood at Rs 10,151 million and net debt to EBITDA at 0.91x Granules India has announced its financial results for the quarter ended December 31, 2025. Revenue from Operations of Q3FY26 stood at Rs 13,879 million, a growth of 22 per cent YoY driven by Finished Dosages (FD) segment in North America and […]
Article by: IMT News Desk
OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26
Finance
January 28, 2026

OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26

Impacted by delayed semaglutide approvals in Canada OneSource has posted the Q3FY26 results. Revenues were at Rs 2,903 million, down 26 per cent YoY, impacted by delayed semaglutide approvals in Canada. The EBITDA was at Rs 173 million, down 88 per cent YoY, due to lower revenue in the quarter and largely fixed cost base. […]
Article by: IMT News Desk
Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr
Finance
January 27, 2026

Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr

Reported revenue dips to Rs 932 crore in the same quarter Syngene International announced financial results for the third quarter of FY26. Peter Bains, Managing Director and CEO, Syngene International, said, “Our Q3 performance reflects the ongoing impact related to a single product from one of our large-molecule biologics clients. Outside of this factor, the […]
Article by: IMT News Desk
Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427
Finance
January 27, 2026

Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427

Sigachi’s entry into CF APIs positions the company in a structurally strong and innovation-led therapeutic segment with long-term demand visibility Sigachi Industries announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor. The development marks […]
Article by: IMT News Desk